| Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma M Sade-Feldman, K Yizhak, SL Bjorgaard, JP Ray, CG de Boer, ... Cell 175 (4), 998-1013. e20, 2018 | 1365 | 2018 |
| Mechanisms of resistance to immune checkpoint inhibitors RW Jenkins, DA Barbie, KT Flaherty British journal of cancer 118 (1), 9, 2018 | 1203 | 2018 |
| A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade L Jerby-Arnon, P Shah, MS Cuoco, C Rodman, MJ Su, JC Melms, ... Cell 175 (4), 984-997. e24, 2018 | 1012 | 2018 |
| CDK4/6 inhibition augments antitumor immunity by enhancing T-cell activation J Deng, ES Wang, RW Jenkins, S Li, R Dries, K Yates, S Chhabra, ... Cancer discovery 8 (2), 216-233, 2018 | 580 | 2018 |
| Ex vivo profiling of PD-1 blockade using organotypic tumor spheroids RW Jenkins, AR Aref, PH Lizotte, E Ivanova, S Stinson, CW Zhou, ... Cancer Discovery 8 (2), 196-215, 2018 | 433 | 2018 |
| Roles and regulation of secretory and lysosomal acid sphingomyelinase RW Jenkins, D Canals, YA Hannun Cellular signalling 21 (6), 836-846, 2009 | 345 | 2009 |
| Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses I Cañadas, R Thummalapalli, JW Kim, S Kitajima, RW Jenkins, ... Nature medicine, 1, 2018 | 243 | 2018 |
| 3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade AR Aref, M Campisi, E Ivanova, A Portell, D Larios, BP Piel, N Mathur, ... Lab on a Chip 18 (20), 3129-3143, 2018 | 213 | 2018 |
| Defining T cell states associated with response to checkpoint immunotherapy in melanoma M Sade-Feldman, K Yizhak, SL Bjorgaard, JP Ray, CG de Boer, ... Cell 176 (1), 404, 2019 | 201 | 2019 |
| Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases D Canals, DM Perry, RW Jenkins, YA Hannun British journal of pharmacology 163 (4), 694-712, 2011 | 196 | 2011 |
| Remodeling of cellular cytoskeleton by the acid sphingomyelinase/ceramide pathway YH Zeidan, RW Jenkins, YA Hannun The Journal of cell biology 181 (2), 335-350, 2008 | 196 | 2008 |
| Regulated Secretion of Acid Sphingomyelinase IMPLICATIONS FOR SELECTIVITY OF CERAMIDE FORMATION RW Jenkins, D Canals, J Idkowiak-Baldys, F Simbari, P Roddy, DM Perry, ... Journal of Biological Chemistry 285 (46), 35706-35718, 2010 | 154 | 2010 |
| Selective knockdown of ceramide synthases reveals complex interregulation of sphingolipid metabolism TD Mullen, S Spassieva, RW Jenkins, K Kitatani, J Bielawski, YA Hannun, ... Journal of lipid research 52 (1), 68-77, 2011 | 137 | 2011 |
| Ceramide synthase-dependent ceramide generation and programmed cell death involvement of salvage pathway in regulating postmitochondrial events TD Mullen, RW Jenkins, CJ Clarke, J Bielawski, YA Hannun, LM Obeid Journal of Biological Chemistry 286 (18), 15929-15942, 2011 | 123 | 2011 |
| Mechanisms of resistance to immune checkpoint blockade D Liu, RW Jenkins, RJ Sullivan American journal of clinical dermatology 20 (1), 41-54, 2019 | 110 | 2019 |
| Autophagy inhibition dysregulates TBK1 signaling and promotes pancreatic inflammation S Yang, Y Imamura, RW Jenkins, I Cañadas, S Kitajima, A Aref, ... Cancer immunology research 4 (6), 520-530, 2016 | 103 | 2016 |
| A novel role for protein kinase Cδ-mediated phosphorylation of acid sphingomyelinase in UV light-induced mitochondrial injury YH Zeidan, BX Wu, RW Jenkins, LM Obeid, YA Hannun The FASEB Journal 22 (1), 183-193, 2008 | 103 | 2008 |
| Response to crizotinib in a patient with lung adenocarcinoma harboring a MET splice site mutation RW Jenkins, GR Oxnard, S Elkin, EK Sullivan, JL Carter, DA Barbie Clinical lung cancer 16 (5), e101-e104, 2015 | 101 | 2015 |
| Defining a role for sphingosine kinase 1 in p53-dependent tumors LA Heffernan-Stroud, KL Helke, RW Jenkins, AM De Costa, YA Hannun, ... Oncogene 31 (9), 1166, 2012 | 86 | 2012 |
| Molecular targeting of acid ceramidase: implications to cancer therapy YH Zeidan, RW Jenkins, JB Korman, X Liu, LM Obeid, JS Norris, ... Current drug targets 9 (8), 653-661, 2008 | 86 | 2008 |
